TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone561-961-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.10 million
Profitability
Miscellaneous
Employees241
Next Earnings Date7/29/2019 (Estimated)
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings data on Monday, May, 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. The company earned $3.95 million during the quarter, compared to analysts' expectations of $5.96 million. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business's revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted ($0.11) earnings per share. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
5 analysts have issued 1 year price objectives for TherapeuticsMD's shares. Their forecasts range from $4.00 to $27.00. On average, they anticipate TherapeuticsMD's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 334.0% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
What are Wall Street analysts saying about TherapeuticsMD stock?
Here are some recent quotes from research analysts about TherapeuticsMD stock:
- 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (5/14/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)
Has TherapeuticsMD been receiving favorable news coverage?
Headlines about TXMD stock have trended positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 79,298,575 shares, an increase of 2.5% from the April 15th total of 77,395,690 shares. Based on an average daily trading volume, of 2,760,062 shares, the short-interest ratio is presently 28.7 days. Approximately 39.9% of the company's shares are sold short. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Amneal Pharmaceuticals (AMRX), Uniqure (QURE), PTC Therapeutics (PTCT), Myokardia (MYOK), Arrowhead Pharmaceuticals (ARWR) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of TherapeuticsMD own?
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (8.47%), FMR LLC (7.54%), BlackRock Inc. (6.39%), Daruma Capital Management LLC (2.95%), Frontier Capital Management Co. LLC (2.43%) and Rubric Capital Management LP (1.94%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., First Eagle Investment Management LLC, Morgan Stanley, Sanders Morris Harris LLC, 1492 Capital Management LLC, TD Asset Management Inc., Oppenheimer & Co. Inc. and Jane Street Group LLC. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
TXMD stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Rubric Capital Management LP, Daruma Capital Management LLC, JPMorgan Chase & Co., SG Americas Securities LLC, Rice Hall James & Associates LLC, J. Goldman & Co LP and C WorldWide Group Holding A S. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $3.18.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $767.09 million and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at sharehold[email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
